CAMBRIDGE — The boom in initial public offerings by biotech startups, which took many by surprise this year, looks likely to continue into 2014. But it could lose some steam if the Federal Reserve starts to withdraw the stimulus that has powered financial markets.
That was the view of industry insiders taking the temperature of the IPO market at a Monday panel sponsored by the New England Healthcare Executives Group, a networking organization for high-ranking executives in the biotech and medical technology businesses
So far in 2013, there have been 34 biotech IPOs nationwide, including nine in Massachusetts, according to data presented by panel moderator Doug MacDougall, president of MacDougall Biomedical Communications, a Wellesley firm that consults with startups. Full story for BostonGlobe.com subscribers.